– USA, NC – Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Dr. Ben Yerxa (Ph.D.) as CEO.
“Opus is entering a pivotal time in its evolution as our first program, OPGx-001 to address mutations in the LCA5 gene, is expected to enter the clinic this year, bringing a potential treatment another step closer to patients in need. As a founder of the RD Fund and Opus, Ben is uniquely well-suited to realize Opus’ potential to tackle some of the most neglected forms of inherited blindness and make a real difference in the lives of patients,” said Dr. Jean Bennett, scientific founder, board director and scientific advisory board member.
Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, the venture arm of the Foundation focused on making venture philanthropy investments to further the Foundation’s mission of accelerating research for preventing, treating and curing blinding diseases.
About Dr. Ben Yerxa
Dr. Ben Yerxa has more than 25 years’ experience in biotechnology, nonprofit and drug development and in translating promising research discoveries into clinical milestones and commercial launches in the ophthalmology, pulmonary, rare disease, cardiovascular and HIV fields. He has been involved with the discovery and development of nine investigational new drugs, four Phase 3 clinical programs, two new drug applications and two drug approvals. Prior to joining the Foundation, Dr. Yerxa served as president and co-founder of Envisia Therapeutics, a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. He also has previously held founding and executive positions in several ophthalmology-based R&D organizations, including Liquidia Technologies, Clearside Biomedical, Parion Sciences and Inspire Pharmaceuticals.
“I’m exceptionally proud of the progress we’ve made toward our mission during my nearly five years at the Foundation, including the launch of the RD Fund to further the Foundation’s mission through venture philanthropy,” said Dr. Ben Yerxa. “Stepping into the permanent CEO role at Opus Genetics – a company that we created and launched through the RD Fund – enables me to be on the front line of bringing potentially life-changing treatments to the patients who so urgently need them.”
Dr. Yerxa holds 60 U.S. patents and is an inventor of DIQUAS, an innovative treatment for dry eye approved in Japan. Dr. Yerxa earned his Ph.D. in organic chemistry from University of California, Irvine, and BA in chemistry from the University of California, San Diego.
About Opus Genetics
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly-owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients.
Opus is the first spin-off company internally conceived and launched by the RD Fund and combines unparalleled insight and commitment to patient need with wholly-owned AAV-based gene therapy programs in inherited retinal diseases while creating novel manufacturing scale and efficiencies tailored for producing rare disease therapeutics.
For more information: https://opusgtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.